Practice guidelines for deep venous thrombosis prophylaxis in burns.
Measures to prevent deep venous thrombosis (DVT), including low-dose subcutaneous heparin, low molecular weight heparin, or sequential compression devices, may be considered in high-risk patients, specifically those with a previous history of thromboembolic disease, and in patients with significant burns of the lower extremities. The purpose of this guideline is to review the principles of prophylaxis for DVT in burn patients and to present a reasonable approach for the treatment of patients during burn resuscitation. This guideline is designed to aid those physicians who are responsible for the triage and initial management of burn patients. DVT in the burn patient is a more common event than previously reported, with incidence ranging from 1% to 23% in the few available series. The suspected risk of bleeding using low-dose heparin has deterred most burn surgeons from using heparin routinely in all burn patients. Much remains unknown, however, regarding the real risks and benefits of this complication and its treatment. A Medline search of all English language citations from 1966 through 2006 was undertaken using the key words "deep vein thrombosis" and "deep venous thrombosis" with "burns." This produced 18 references. The addition of the key words "pulmonary embolism" with "burns" produced a total of 82 references, of which 7 were felt to be relevant to this topic based on evidentiary classification of the data. There are no prospective, randomized, controlled studies evaluating the effectiveness of any prophylactic preventive measures against DVT in burn patients. The apparently low incidence of this condition in burn patients would appear to preclude its evaluation in a single-center study, and no multicenter studies have been conducted.
Faucher
Lee D
LD
University of Wisconsin, Madison, Wisconsin 53792, USA.
Conlon
Kathe M
KM
D000925:Anticoagulants / Q000627:therapeutic use; D002056:Burns / Q000150:complications* / Q000503:physiopathology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D017410:Practice Guidelines as Topic; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000517:prevention & control; D012307:Risk Factors; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
D000925:Anticoagulants; D006493:Heparin